SG10201806565SA - Heterocyclic carboxylic acids as activators of soluble guanylate cyclase - Google Patents

Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Info

Publication number
SG10201806565SA
SG10201806565SA SG10201806565SA SG10201806565SA SG10201806565SA SG 10201806565S A SG10201806565S A SG 10201806565SA SG 10201806565S A SG10201806565S A SG 10201806565SA SG 10201806565S A SG10201806565S A SG 10201806565SA SG 10201806565S A SG10201806565S A SG 10201806565SA
Authority
SG
Singapore
Prior art keywords
activators
carboxylic acids
guanylate cyclase
soluble guanylate
compounds
Prior art date
Application number
SG10201806565SA
Inventor
Jehrod Burnett Brenneman
John David Ginn
Christopher Ronald Sarko
John Westbrook
Zhonghua Zhang
Maolin Yu
Tamara Denise Hopkins
Michael D Lowe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201806565S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG10201806565SA publication Critical patent/SG10201806565SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Heterocyclic Carboxylic Acids as Activators of Soluble Guanylate Cyclase The present invention relates to compounds of formula I: O R 5 R 6 Y W R 8 R 7 Z N V R 9 N X O O H R 1 R 2 R 3 B m I and pharmaceutically acceptable salts thereof, wherein R 1 , R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. [No Available Figure] 229
SG10201806565SA 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase SG10201806565SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462027376P 2014-07-22 2014-07-22

Publications (1)

Publication Number Publication Date
SG10201806565SA true SG10201806565SA (en) 2018-08-30

Family

ID=53783363

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700507XA SG11201700507XA (en) 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
SG10201806565SA SG10201806565SA (en) 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201700507XA SG11201700507XA (en) 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Country Status (26)

Country Link
US (1) US9353090B2 (en)
EP (1) EP3172202B1 (en)
JP (1) JP6602840B2 (en)
KR (1) KR20170035993A (en)
CN (1) CN106459017B (en)
AP (1) AP2016009615A0 (en)
AR (1) AR101265A1 (en)
AU (1) AU2015292833B2 (en)
BR (1) BR112017000943A2 (en)
CA (1) CA2955937A1 (en)
CL (1) CL2017000071A1 (en)
CO (1) CO2017000438A2 (en)
DK (1) DK3172202T3 (en)
EA (1) EA032972B1 (en)
ES (1) ES2784477T3 (en)
HU (1) HUE049231T2 (en)
IL (1) IL249587A0 (en)
MX (1) MX2017000926A (en)
PE (1) PE20170249A1 (en)
PH (1) PH12017500111A1 (en)
PL (1) PL3172202T3 (en)
PT (1) PT3172202T (en)
SG (2) SG11201700507XA (en)
TW (1) TWI711615B (en)
UY (1) UY36226A (en)
WO (1) WO2016014463A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411026B1 (en) * 2016-02-01 2022-03-09 Cyclerion Therapeutics, Inc. Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
SI3795576T1 (en) 2016-09-14 2023-08-31 Genomatica, Inc. 1,3-fatty diol compounds and glycosylated derivatives thereof
JP7237823B2 (en) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Combinations comprising SGC activators and mineralocorticoid receptor antagonists
CN106495999B (en) * 2016-10-18 2019-08-16 亳州学院 A kind of aromatic aldehyde and its synthetic method
CN110891954A (en) 2017-07-14 2020-03-17 葛兰素史密斯克莱知识产权发展有限公司 Inhibitors of leucine-rich repeat kinase 2
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Use of activators and stimulators of sgc comprising a beta2 subunit
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EP3784238A4 (en) * 2018-04-27 2021-12-29 Hetero Labs Ltd. Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
WO2019211081A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
MX2020012230A (en) 2018-05-15 2021-01-29 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization.
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
EA202191554A1 (en) 2018-12-03 2021-09-02 Фмк Корпорейшн METHOD FOR OBTAINING N-PHENYLPYRAZOL-1-CARBOXAMIDES
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN114957087A (en) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 Preparation method of intermediate of palovaried
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
CA2615426A1 (en) 2005-07-18 2007-01-25 Bayer Healthcare Ag Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
AU2008250643A1 (en) 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC stimulators, sGC activators and combinations for the treatment of urological disorders
MX2010002608A (en) 2007-09-06 2010-06-01 Merck Sharp & Dohme Soluble guanylate cyclase activators.
BRPI0817483A2 (en) 2007-10-05 2016-07-26 Sanofi Aventis Deutschland use of sulfonyl substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (en) 2007-12-03 2009-07-17 PIRIDINE DERIVATIVES SOLUBLE CYCLING GUANILATE ACTIVATORS
JP5432890B2 (en) 2008-04-04 2014-03-05 武田薬品工業株式会社 Heterocyclic derivatives and uses thereof
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
AU2010205931A1 (en) 2009-01-17 2011-07-28 Bayer Schering Pharma Aktiengesellschaft sGC stimulators of sGC activators in combination with PDE5 inhibitors for the treatment of erectile dysfunction
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
MY159697A (en) 2010-02-05 2017-01-13 Adverio Pharma Gmbh Sgc stimulators or sgc activators alone and in combination with pde5 inhibitors for the treatment of cystic fibrosis
NZ603799A (en) 2010-05-26 2014-10-31 Bayer Ip Gmbh The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
WO2011161099A1 (en) 2010-06-25 2011-12-29 Bayer Pharma Aktiengesellschaft Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
JP5826393B2 (en) * 2011-08-12 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Soluble guanylate cyclase activator
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
RS59394B1 (en) * 2012-09-07 2019-11-29 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma

Also Published As

Publication number Publication date
CN106459017B (en) 2020-07-17
CN106459017A (en) 2017-02-22
DK3172202T3 (en) 2020-04-27
EP3172202B1 (en) 2020-01-29
ES2784477T3 (en) 2020-09-28
SG11201700507XA (en) 2017-02-27
BR112017000943A2 (en) 2017-11-14
EA201790246A1 (en) 2017-07-31
AP2016009615A0 (en) 2016-12-31
CO2017000438A2 (en) 2017-08-31
TW201617340A (en) 2016-05-16
AR101265A1 (en) 2016-12-07
WO2016014463A1 (en) 2016-01-28
PL3172202T3 (en) 2020-07-13
TWI711615B (en) 2020-12-01
JP6602840B2 (en) 2019-11-06
IL249587A0 (en) 2017-02-28
EA032972B1 (en) 2019-08-30
PH12017500111A1 (en) 2017-05-29
PT3172202T (en) 2020-05-06
AU2015292833A1 (en) 2016-12-22
CL2017000071A1 (en) 2017-06-30
UY36226A (en) 2016-01-29
CA2955937A1 (en) 2016-01-28
MX2017000926A (en) 2017-05-04
AU2015292833B2 (en) 2019-11-28
EP3172202A1 (en) 2017-05-31
US20160024059A1 (en) 2016-01-28
PE20170249A1 (en) 2017-04-05
KR20170035993A (en) 2017-03-31
US9353090B2 (en) 2016-05-31
JP2017521457A (en) 2017-08-03
HUE049231T2 (en) 2020-09-28

Similar Documents

Publication Publication Date Title
SG10201806565SA (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
UA115881C2 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2012122340A8 (en) Soluble guanylate cyclase activators
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
MD20140063A2 (en) Benzothiazol-6-il acetic acid derivatives and their use for treating an HIV infection
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
EA201792597A3 (en) GLUTARIMIDES DERIVATIVES, THEIR APPLICATION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS, METHODS OF THEIR PRODUCTION
MD20160105A2 (en) 2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
WO2017177004A8 (en) Tertiary amides and method of use
PH12017500595B1 (en) Aldosterone synthase inhibitors
PH12017500089B1 (en) Aldosterone synthase inhibitors
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production